Ptc Therapeutics (PTCT) |
|
57 -0.32 (-0.56%)
|
03-03 16:40 |
|
Open: |
57.42 |
Pre. Close: |
57.32 |
|
High:
|
58.015 |
Low:
|
56.44 |
|
Volume:
|
390,520 |
Market Cap:
|
4,008M |
|
|
|
|
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
58.819 - 59.129 |
59.129 - 59.392 |
|
Low:
|
56.359 - 56.709 |
56.709 - 57.006 |
|
Close:
|
56.749 - 57.339 |
57.339 - 57.842 |
|
Technical analysis |
as of: 2021-03-03 4:08:22 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 71.74 One year: 77.10 |
| Support: |
Support1: 54.00 Support2: 44.93 |
| Resistance: |
Resistance1: 61.42 Resistance2: 66.01 |
| Pivot: |
58.83 |
| Moving Average: |
MA(5): 56.97 MA(20): 59.88
MA(100): 60.53  MA(250): 53.28 |
| MACD: |
MACD(12,26): -1.50 Signal(9): -1.35 |
| Stochastic oscillator: |
%K(14,3): 30.16 %D(3): 26.80 |
| RSI: |
RSI(14): 40.47 |
| 52-week: |
High: 70.82 Low: 30.79 Change(%): 3.0 |
| Average Vol(K): |
3-Month: 51644 10-Days: 53959 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.PTCT has closed above bottom band by 31.4%. Bollinger Bands are 0.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Wed, 03 Mar 2021
Analysts Offer Insights on Healthcare Companies: Antares Pharma (ATRS) and PTC Therapeutics (PTCT) - Smarter Analyst
Fri, 26 Feb 2021
When Will PTC Therapeutics, Inc. (NASDAQ:PTCT) Become Profitable? - Simply Wall St
Fri, 26 Feb 2021
PTC Therapeutics, Inc (PTCT) CEO Stuart Peltz on Q4 2020 Results - Earnings Call Transcript - Seeking Alpha
Thu, 25 Feb 2021
PTC Therapeutics: 4Q Earnings Snapshot - San Francisco Chronicle
Thu, 25 Feb 2021
PTC Therapeutics EPS misses by $0.15, beats on revenue - Seeking Alpha
Thu, 25 Feb 2021
PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
68 |
| Shares Float (M) |
63 |
|
% Held by Insiders
|
2.91 |
|
% Held by Institutions
|
106.46 |
|
Shares Short (K)
|
4,200 |
|
Shares Short P. Month (K)
|
4,910 |
Stock Financials |
|
EPS
|
-6.860 |
|
EPS Est This Year
|
-2.350 |
|
EPS Est Next Year
|
-1.970 |
|
Book Value (p.s.)
|
7.530 |
|
Profit Margin
|
-123.20 |
|
Operating Margin
|
-87.59 |
|
Return on Assets (ttm)
|
-10.3 |
|
Return on Equity (ttm)
|
-75.2 |
|
Qtrly Rev. Growth
|
65.8 |
|
Gross Profit (p.s.)
|
0.548 |
|
Sales Per Share
|
5.251 |
|
EBITDA (p.s.)
|
-4.008 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-140 |
|
Levered Free Cash Flow (M)
|
-103 |
Stock Valuations |
|
PE Ratio
|
-8.32 |
|
PEG Ratio
|
|
|
Price to Book value
|
7.58 |
|
Price to Sales
|
10.87 |
|
Price to Cash Flow
|
-27.85 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
